維格列汀(英語:Vildagliptin),商品名為高糖優適,是一種二肽基肽酶-4抑制劑類口服抗糖尿病藥,用來治療第2型糖尿病[2][3][3][2]

維格列汀
Skeletal formula
Ball-and-stick model
臨床資料
商品名英語Drug nomenclatureGalvus
其他名稱(2S)-1-{2-[(3-hydroxy-1-adamantyl)amino]acetyl}pyrrolidine-2-carbonitrile
AHFS/Drugs.com國際藥品名稱
核准狀況
懷孕分級
  • Not recommended
給藥途徑口服
ATC碼
法律規範狀態
法律規範
藥物動力學數據
生物利用度85%
血漿蛋白結合率9.3%
藥物代謝主要水解為非活性代謝物; CYP450沒有明顯參與
生物半衰期2-3小時
排泄途徑腎臟
識別資訊
  • (S)-1-[N-(3-hydroxy-1-adamantyl)glycyl]pyrrolidine-2-carbonitrile
CAS號274901-16-5  checkY
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
ECHA InfoCard100.158.712 編輯維基數據鏈接
化學資訊
化學式C17H25N3O2
摩爾質量303.399 g/mol
3D模型(JSmol英語JSmol
  • N#C[C@H]4N(C(=O)CNC13CC2CC(C1)CC(O)(C2)C3)CCC4
  • InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1 checkY
  • Key:SYOKIDBDQMKNDQ-XWTIBIIYSA-N checkY

維格列汀是唯一一種無論在高血糖或低血糖時都可以抑制胰高血糖素的物質。

引用

編輯
  1. ^ WHO International Working Group for Drug Statistics Methodology. ATC/DDD Classification (FINAL): New ATC 5th level codes. WHO Collaborating Centre for Drug Statistics Methodology. August 27, 2008 [2008-09-05]. (原始內容存檔於2008年5月6日). 
  2. ^ 2.0 2.1 Ahrén, B; Landin-Olsson, M; Jansson, PA; Svensson, M; Holmes, D; Schweizer, A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism. 2004, 89 (5): 2078–84 [2015-08-30]. PMID 15126524. doi:10.1210/jc.2003-031907. (原始內容存檔於2011-05-16). 
  3. ^ 3.0 3.1 Mentlein, R; Gallwitz, B; Schmidt, WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. European journal of biochemistry / FEBS. 1993, 214 (3): 829–35. PMID 8100523. doi:10.1111/j.1432-1033.1993.tb17986.x.